Newbridge Financial Services Group Inc. Reduces Stake in Novo Nordisk A/S (NYSE:NVO)

Newbridge Financial Services Group Inc. reduced its position in Novo Nordisk A/S (NYSE:NVO) by 97.3% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 548 shares of the company’s stock after selling 19,642 shares during the period. Newbridge Financial Services Group Inc.’s holdings in Novo Nordisk A/S were worth $47,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently modified their holdings of NVO. Daiwa Securities Group Inc. purchased a new position in Novo Nordisk A/S during the third quarter valued at $28,000. Capital Performance Advisors LLP purchased a new position in shares of Novo Nordisk A/S in the third quarter valued at about $42,000. Carolina Wealth Advisors LLC purchased a new position in shares of Novo Nordisk A/S in the third quarter valued at about $48,000. Dunhill Financial LLC lifted its position in shares of Novo Nordisk A/S by 196.8% in the third quarter. Dunhill Financial LLC now owns 469 shares of the company’s stock valued at $56,000 after acquiring an additional 311 shares in the last quarter. Finally, Albion Financial Group UT lifted its position in shares of Novo Nordisk A/S by 121.4% in the fourth quarter. Albion Financial Group UT now owns 507 shares of the company’s stock valued at $44,000 after acquiring an additional 278 shares in the last quarter. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Novo Nordisk A/S Trading Down 0.2 %

NVO opened at $83.78 on Wednesday. The stock has a market cap of $375.95 billion, a price-to-earnings ratio of 25.46, a P/E/G ratio of 0.96 and a beta of 0.45. The stock’s 50 day moving average price is $90.96 and its 200-day moving average price is $110.91. Novo Nordisk A/S has a one year low of $78.17 and a one year high of $148.15. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.75 and a current ratio of 0.74.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, beating analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. On average, equities analysts forecast that Novo Nordisk A/S will post 3.86 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The firm also recently announced a semi-annual dividend, which will be paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st will be paid a dividend of $0.7874 per share. This is a boost from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. The ex-dividend date of this dividend is Monday, March 31st. This represents a dividend yield of 1.2%. Novo Nordisk A/S’s dividend payout ratio is currently 47.72%.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on NVO. BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. BMO Capital Markets reduced their target price on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a report on Monday, December 23rd. StockNews.com cut Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. Finally, UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $145.25.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.